Fetal-maternal haemorrhage
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC
| Fetal-maternal haemorrhage | |
|---|---|
| File:Kleihauer.JPG | |
| Synonyms | Fetomaternal hemorrhage, FMH |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Decreased fetal movement, fetal distress |
| Complications | Fetal anemia, hydrops fetalis, stillbirth |
| Onset | During pregnancy or labor |
| Duration | Acute or chronic |
| Types | N/A |
| Causes | Trauma, placental abruption, invasive procedures |
| Risks | Rh incompatibility, placenta previa, multiple gestation |
| Diagnosis | Kleihauer-Betke test, flow cytometry |
| Differential diagnosis | Placental abruption, preterm labor |
| Prevention | Rho(D) immune globulin administration |
| Treatment | Intrauterine transfusion, early delivery |
| Medication | N/A |
| Prognosis | Depends on severity and treatment |
| Frequency | Occurs in up to 1% of pregnancies |
| Deaths | N/A |
Fetal-maternal haemorrhage (FMH) is a medical condition that occurs when fetal blood cells cross the placenta and enter the maternal circulation. This phenomenon can have significant clinical implications, particularly in the context of Rh incompatibility and other blood group incompatibilities.
Pathophysiology[edit]
FMH can occur during pregnancy or delivery. The placenta, which normally acts as a barrier between the maternal and fetal blood supplies, can allow fetal red blood cells to pass into the maternal circulation under certain conditions. This transfer can happen due to trauma, placental abruption, or during normal labor and delivery. The amount of fetal blood that enters the maternal circulation can vary significantly, from a few milliliters to more than 30 mL. In most pregnancies, small amounts of fetal blood enter the maternal circulation without causing any problems. However, significant FMH can lead to maternal sensitization to fetal antigens, particularly the RhD antigen, resulting in hemolytic disease of the newborn in subsequent pregnancies.
Clinical Significance[edit]
FMH is particularly important in Rh-negative mothers carrying an Rh-positive fetus. If fetal red blood cells enter the maternal circulation, the mother may produce antibodies against the Rh antigen. These antibodies can cross the placenta in future pregnancies and attack the red blood cells of an Rh-positive fetus, leading to hemolytic disease of the newborn.
Diagnosis[edit]
The diagnosis of FMH can be made using several laboratory techniques. The most common method is the Kleihauer-Betke test, which involves staining maternal blood samples to identify fetal red blood cells. In this test, fetal red blood cells appear as bright pink cells against a background of pale maternal cells. The test can estimate the volume of fetal blood in the maternal circulation, which is crucial for determining the need for interventions such as Rho(D) immune globulin administration.
Management[edit]
The management of FMH depends on the volume of fetal blood that has entered the maternal circulation and the Rh status of the mother. In Rh-negative mothers, the administration of Rho(D) immune globulin can prevent sensitization. This prophylactic treatment is typically given at 28 weeks of gestation and within 72 hours of delivery if the newborn is Rh-positive. In cases of massive FMH, the fetus may require intrauterine transfusions to manage anemia. Postnatally, affected newborns may need phototherapy or exchange transfusions to treat hyperbilirubinemia and anemia.
Prevention[edit]
Preventive measures for FMH focus on minimizing trauma during pregnancy and delivery. Routine administration of Rho(D) immune globulin to Rh-negative mothers has significantly reduced the incidence of hemolytic disease of the newborn due to Rh incompatibility.
